(Reuters) – The U.S. Food and Drug Administration said on Tuesday it had approved Takeda Pharmaceutical Co Ltd’s Livtencity for a common type of post-transplant infection.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva)
U.S. FDA approves Takeda’s drug for post-transplant infection
Nov 23, 2021 | 5:21 PM
